Effectiveness of Atenolol on the Basis of Pattern of Side Effects in Hypertensive Patients
Effectiveness of Atenolol in Hypertensive Patients
DOI:
https://doi.org/10.54393/df.v4i01.68Keywords:
Hypertension, Atenolol, InsulinAbstract
Hypertension plays a significant role in changing Insulin parameter. They are taken as valid diagnostic markers in determining side effects of anti-hypertensive drugs. These parameters are grossly affected by the use of beta blockers which are used to control hypertension. Objective: To determine the effects of atenolol, a beta blocker on insulin when taking alone in hypertensive patients. Methods: A total of 80 patients participated in this study of which 43 patients were taking atenolol alone while 37 were taking atenolol in combination with other anti-hypertensive drugs and 20 healthy controls were included of all age groups population to make a comparison and to find variation in values of insulin levels, in patients experiencing hypertension. Medical efficacy was evaluated on the basis of variations in insulin levels upon use of anti-hypertensive medications. ELISA technique was used for conducting insulin levels. Results: We found significant results of insulin values because atenolol cause hyperglycemia Atenolol was non-significant in both groups of patients having low insulin levels due to use of atenolol alone or use of atenolol in combination therapy. Other anti-hypertensive drugs did not affect the insulin levels therefore variation is basically because of atenolol so the main focus of our study was atenolol. Conclusions: Atenolol prove efficacy but it also causes the disturbance in insulin levels therefore we recommend use of any other drug in conjunction with atenolol to avoid insulin variation due to atenolol. Further these results may be employed on large patient population for strengthening our evidences.
References
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003 Dec; 42(6): 1206-52. doi: 10.1161/01.HYP.0000107251.49515.c2. DOI: https://doi.org/10.1161/01.HYP.0000107251.49515.c2
Carretero OA and Oparil S. Essential hypertension: part I: definition and etiology. Circulation. 2000 Jan; 101(3): 329-35. doi: 10.1161/01.CIR.101.3.329. DOI: https://doi.org/10.1161/01.CIR.101.3.329
Marshall IJ, Wolfe CD, McKevitt C. Lay perspectives on hypertension and drug adherence: systematic review of qualitative research. Bmj. 2012 Jul; 345. doi: 10.1136/bmj.e3953. DOI: https://doi.org/10.1136/bmj.e3953
Corvol P, Persu A, Gimenez-Roqueplo AP, Jeunemaitre X. Seven lessons from two candidate genes in human essential hypertension: angiotensinogen and epithelial sodium channel. Hypertension. 1999 Jun; 33(6): 1324-31. doi: 10.1161/01.HYP.33.6.1324. DOI: https://doi.org/10.1161/01.HYP.33.6.1324
Feinleib MR, Garrison RJ, Fabsitz R, Christian JC, Hrubec Z, Borhani NO, et al. The NHLBI twin study of cardiovascular disease risk factors: methodology and summary of results. American Journal of Epidemiology. 1977 Oct; 106(4): 284-95. doi: 10.1093/oxfordjournals.aje.a112464. DOI: https://doi.org/10.1093/oxfordjournals.aje.a112464
Biron PI, Mongeau JG, Bertrand DE. Familial aggregation of blood pressure in 558 adopted children. Canadian Medical Association Journal. 1976 Oct; 115(8): 773.
Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension. Cell. 2001 Feb; 104(4): 545-56. doi: 10.1016/S0092-8674(01)00241-0. DOI: https://doi.org/10.1016/S0092-8674(01)00241-0
Wilson FH, Disse-Nicodeme S, Choate KA, Ishikawa K, Nelson-Williams C, Desitter I, et al. Human hypertension caused by mutations in WNK kinases. Science. 2001 Aug ;293(5532): 1107-12. doi: 10.1126/science.1062844. DOI: https://doi.org/10.1126/science.1062844
Guyton AC. Blood pressure control—special role of the kidneys and body fluids. Science. 1991 Jun; 252(5014): 1813-6. doi: 10.1126/science.2063193. DOI: https://doi.org/10.1126/science.2063193
Somers VK, Anderson EA, Mark AL. Sympathetic neural mechanisms in human hypertension. Current Opinion in Nephrology and Hypertension. 1993 Jan; 2(1): 96-105. doi: 10.1097/00041552-199301000-00015. DOI: https://doi.org/10.1097/00041552-199301000-00015
Takahashi H. Sympathetic hyperactivity in hypertension. Nihon rinsho. Japanese Journal of Clinical Medicine. 2008 Aug; 66(8): 1495-502.
Esler M. The sympathetic system and hypertension. American Journal of Hypertension. 2000 Jun; 13(S4): 99S-105S. doi: 10.1016/S0895-7061(00)00225-9. DOI: https://doi.org/10.1016/S0895-7061(00)00225-9
Fujino T, Nakagawa N, Yuhki KI, Hara A, Yamada T, Takayama K, et al. Decreased susceptibility to renovascular hypertension in mice lacking the prostaglandin I 2 receptor IP. The Journal of Clinical Investigation. 2004 Sep; 114(6): 805-12. doi: 10.1172/JCI21382. DOI: https://doi.org/10.1172/JCI21382
Singh TB and Haldar P. Anxiety disorders induced hypertention: issue clinical care. Journal of Evolution of Medical and Dental Sciences. 2014 Sep; 3(42): 10428-33. doi: 10.14260/jemds/2014/3362. DOI: https://doi.org/10.14260/jemds/2014/3362
Mark AL. The sympathetic nervous system in hypertension: a potential long-term regulator of arterial pressure. Journal of hypertension. Supplement: Official Journal of the International Society of Hypertension. 1996 Dec; 14(5): S159-65.
Palatini P and Julius S. The role of cardiac autonomic function in hypertension and cardiovascular disease. Current Hypertension Reports. 2009 Jun; 11(3): 199-205. doi: 10.1007/s11906-009-0035-4. DOI: https://doi.org/10.1007/s11906-009-0035-4
Bühler FR, Vesanen K, Watters JT, Bolli P. Impact of smoking on heart attacks, strokes, blood pressure control, drug dose, and quality of life aspects in the International Prospective Primary Prevention Study in Hypertension. American Heart Journal. 1988 Jan; 115(1): 282-8. doi: 10.1016/0002-8703(88)90651-5. DOI: https://doi.org/10.1016/0002-8703(88)90651-5
McCourt C, Coleman HG, Murray LJ, Cantwell MM, Dolan O, Powe DG, et al. Beta‐blocker usage after malignant melanoma diagnosis and survival: a population‐based nested case–control study. British Journal of Dermatology. 2014 Apr; 170(4): 930-8. doi: 10.1111/bjd.12894. DOI: https://doi.org/10.1111/bjd.12894
Livingstone E, Hollestein LM, van Herk-Sukel MP, van de Poll-Franse L, Nijsten T, Schadendorf D, et al. β-Blocker use and all-cause mortality of melanoma patients: results from a population-based Dutch cohort study. European Journal of Cancer. 2013 Dec; 49(18): 3863-71. doi: 10.1016/j.ejca.2013.07.141. DOI: https://doi.org/10.1016/j.ejca.2013.07.141
Zusman RM. The role of alpha1‐blockers in combination therapy for hypertension. International Journal of Clinical Practice. 2000 Jan; 54(1): 36-41. doi: 10.1111/j.1742-1241.2000.tb11839.x. DOI: https://doi.org/10.1111/j.1742-1241.2000.tb11839.x
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 DIET FACTOR (Journal of Nutritional & Food Sciences)
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access journal and all the published articles / items are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. For comments
